FDA Official Stresses "Flexibility" On Speeding Approval Of Drugs That Truly Stand Out

Four-year study of cancer drugs shows tyrosine kinase inhibitors commonly get cleared based on Phase II data in both accelerated and regular approvals. Emerging new classes could find faster paths.